AbbVie Beats Q3, Lifts 2026 EPS Outlook and Raises Dividend 5.2%
ABBV sits 54% above its 52-week low of $190.75.
Summary
AbbVie beat on both lines: Q3 sales of $17.404 billion rose 10.3% and topped the $17.314 billion consensus, while adjusted EPS of $3.82 cleared the $3.75 estimate. Immunology did the heavy lifting — Skyrizi up 22.7% to $5.776 billion and Rinvoq up 23.9% to $2.706 billion — more than offsetting Humira's 31.2% decline to $683 million. Management raised full-year 2026 revenue guidance to $67.8 billion from $67.6 billion and adjusted EPS to $13.95-$13.99 from $13.76-$13.96, both above consensus, and lifted the quarterly dividend 5.2% to $1.82 from $1.73, payable Feb. 16, 2027. The stock rose 1.93% to $296.41, a new 52-week high, putting it within a few dollars of the $298.74 high. This follows the 8-K filed this morning and the string of positive catalysts since August — the EU Rinvoq approval, the etentamig Phase 3 win, the Qulipta data and the September FDA approval of JUVMO — with the pending $10.9 billion Apogee Therapeutics acquisition funded by the $10 billion bond deal still in the pipeline.
At the time of this announcement, ABBV was trading at $294.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $520.5B. The 52-week trading range was $190.75 to $298.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.